Abnormal values of novel and traditional inflammatory markers such as hsCRP, IL-6, TNF-a, galectin-3, myeloperoxidase (MPO), ST-2, growth differentiation factor (GDF)-15, and microRNAs have been described to be detected in cancer patients with drug induced cardiotoxicity; however it still remains unclear in many cases, whether the inflammatory activation pathway is the result of an ongoing malignancy or a direct result of cardiotoxicity after treatment schemes (23). The gene discussed is MPO; the disease is cancer.